BnR Summit 2026

Belt & Road Summit - Deal-Making 2026

9 – 15 Sept 2026 | Hong Kong, China (Hong Kong)

ProjectUpdated on 19 August 2026

Nose Cancer Vaccine

CEO at Grid Biosciences

China

About

Grid's nose cancer vaccine (against EBV) is currently in a Phase 1 clinical trial. The target market is a global opportunity of $31B USD, as validated by Merck's $922.5M and Lilly's $1.55B EBV deal. Grid is targeting Phase 2 and its strategic options.

Project Location

  • United States

Project Format

  • Private Project

Go Global Project

  • Yes

ESG (Environmental, Social, and Governance)

  • Yes

Project Stage

  • Investment / Financing Discussion

Main Project Sector

  • Technology

Technology

  • Bio-Tech

Type(s) of Last Financing Round of the project (if Applicable)

  • Equity (private)

Main Service(s) Required

  • Financial Services

Organisation

Grid Biosciences

China (Hong Kong)

Similar opportunities